摘要
目的:评价消癌平注射液在恶性肿瘤化疗中增效减毒作用。方法:采用Cochrane循证医学系统评价方法,检索消癌平注射液联合化疗治疗恶性肿瘤的随机对照试验,筛选合格试验进行文献质量评价,采用Rev Man 4.2和Stata12.0进行统计学处理。结果:共纳入9篇符合纳入标准的文献,Jadad评分均小于3分。Meta分析结果显示:纳入文献不存在发表偏倚;与单纯化疗相比,消癌平注射液联合化疗能够提高化疗近期疗效的有效率[OR=1.88,95%CI(1.31,2.71)],提高生活质量的改善率[OR=3.36,95%CI(2.19,5.15)],降低白细胞下降的发生率[OR=0.48,95%CI(0.31,0.73)],其差异均有统计学意义(均P〈0.01);消癌平注射液联合化疗治疗后的血红蛋白和血小板下降发生率总体OR值分别为0.65、0.72,95%CI分别为0.34~1.21、0.40~1.29,差异均无统计学意义(均P〉0.05)。结论:消癌平注射液对化疗治疗恶性肿瘤具有协同增效、提高生活质量和减轻白细胞毒性反应等作用。由于纳入研究的质量偏低,尚需要高质量、设计严谨、多中心的随机对照试验进一步评价。
Objective:To evaluate the enhancing efficient and reducing toxieity of Xiaoaiping injection in tumor chemotherapy. Methods:Using Systematic Evaluation Methods of Cochrane Evidence-Based Medicine,Randomized controlled trials about Xiaoaiping injection combined with chemotherapy for patients with malignant tumor Were searched overall,choosed qualified studies and used Rev Man4.2 and Stata12.0 to perform data analysis. Results:There were 9 documents were included into the meta analysis. Jadad grade showed that the grades of all studies were less than 3 scores. Publish bias didn't exist. The meta analysis showed that compared to chemotherapy only,the Xiaoaiping injection combined with chemotherapy could enhance the efficient of short-term curative effect[OR=1.88,95%CI(1.31,2.71)],improve the quality of life[OR=3.36,95%CI(2.19,5.15)],and reduce the incidence rate of the drop for WBC[OR=0.48,95%CI(0.31,0.73)],they all had significance statistically(Value P〈0.01);In reducing the incidence rate of the drop for Hb and PLT,OR values were 0.65,0.72,95%CI were 0.34~1.21,0.40~1.29,and they all had no significance statistically(Value P〉0.05). Conclusion:Xiaoaiping injection can enhance efficient and reduce toxicity,when combined with chemotherapy for patient with malignant tumor. Owing to the quality of documents was low,It is necessary to conduct Well-designed multi-center randomized-controlled trials of high quality for further evaluation.
出处
《辽宁中医药大学学报》
CAS
2015年第10期73-76,共4页
Journal of Liaoning University of Traditional Chinese Medicine
基金
江苏省中医药管理局基金项目(LZ09030)